Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome

Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Miki, Itonaga, Hidehiro, Nannya, Yasuhito, Taniguchi, Hirokazu, Fukuda, Yuichi, Furumoto, Takafumi, Fujioka, Machiko, Kasai, Sachie, Taguchi, Masataka, Taniguchi, Hiroaki, Sato, Shinya, Sawayama, Yasushi, Atogami, Sunao, Iwasaki, Keisuke, Hata, Tomoko, Soda, Hiroshi, Moriuchi, Yukiyoshi, Nakata, Koh, Ogawa, Seishi, Miyazaki, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205539/
https://www.ncbi.nlm.nih.gov/pubmed/31875636
http://dx.doi.org/10.2169/internalmedicine.3770-19
Descripción
Sumario:Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment.

Ejemplares similares